Item type |
学内発行雑誌 / Departmental Bulletin Paper(1) |
公開日 |
2021-03-18 |
タイトル |
|
|
タイトル |
Efficacy of Mepolizumab for Long-term Treatment in Patients with Severe Asthma |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ |
departmental bulletin paper |
著者 |
MIYATA, Yoshito
OHTA, Shin
TANAKA, Akihiko
AKIMOTO, Kaho
SATO, Hiroki
UNO, Tomoki
SATO, Haruna
UCHIDA, Yoshitaka
JINNO, Megumi
HIRAI, Kuniaki
INOUE, Hideki
HONMA, Tetsuya
YAMAMOTO, Mayumi
SUZUKI, Shintaro
SAGARA, Hironori
|
書誌情報 |
The Showa University journal of medical sciences
巻 32,
号 4,
p. 247-256,
発行日 2021-01
|
抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Mepolizumab is a monoclonal antibody against interleukin-5 used for the treatment of severe asthma. The effect of long-term mepolizumab administration and its persistence in clinical practice is poorly understood. Thus, this study aimed to investigate the effect of long-term administration of mepolizumab in patients with severe asthma. Mepolizumab was administered to 20 patients with severe asthma. We then prospectively followed the patients for 104 weeks to investigate the efficacy of long-term mepolizumab administration in clinical practice. Eleven patients were evaluated for 104 weeks. Mepolizumab administration reduced asthma exacerbations in a year from 52 to 104 weeks and improved asthma control in every period as assessed by questionnaires. Also, blood eosinophil counts decreased at every point, and blood basophil counts decreased at 104 weeks. We compared various parameters among the 11 patients who continued administration for more than 104 weeks and 7 patients who discontinued treatment due to ineffectiveness. Significant differences were observed in disease duration, maximum expiratory flow at 50%, and blood basophil count. Long-term mepolizumab administration improved asthma symptoms in patients with severe asthma and reduced the frequency of exacerbations. |
DOI |
|
|
|
関連識別子 |
10.15369/sujms.32.247 |
出版者 |
|
|
出版者 |
Showa University Society |
ISSN |
|
|
収録物識別子 |
2185-0968 |
著者版フラグ |
|
|
出版タイプ |
VoR |